Specific recommendations for implantation of each prosthesis , taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors , may be needed to reduce the risk of PPI
Aims The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation ( PPI ) after transcatheter aortic valve implantation ( TAVI ) with new-generation prostheses remains debated .
This systematic review analyses the incidence of PPI after TAVI  with new-generation devices and evaluates the electrical , anatomical , and procedural factors associated with PPI .
In addition , the incidence of PPI after  TAVI with early generation prostheses was review ed for comparison .
Transcatheter aortic valve implantation using the ACURATE TA and ACURATE neo valves: a four-year single-centre experience.
AIMS Long-term outcomes are available for first-generation transcatheter heart valves but data on second-generation devices are scarce . We aim ed to provide an oversight of all patients implanted with a second-generation valve in our centre . METHODS AND RESULTS From April 2012 to July 2016 , 219 patients were enrolled in this prospect i ve single-centre experience ; they received either the transapical ACURATE TA ( n=99 ) or the transfemoral ACURATE neo ( n=120 ) prosthesis . Data were collected during the hospital stay and telephone follow-ups were conducted at 30 days post procedure and annually thereafter . Patients were 80.9±4.4 years old with a mean logistic EuroSCORE I of 19.3±13.9 % . Transapical patients had significantly more comorbidities at baseline . Post intervention , mean gradient was reduced to 10.6±9.2 mmHg , and 1.9 % had moderate paravalvular regurgitation . Mean follow-up time , based on the last patient contact , was 217±188 days for the transfemoral and 525±413 days for the transapical group . Thirty-day mortality was 2.5 % and 4.0 % , and one-year Kaplan-Meier survival was 94.8 % ( 95 % CI : 87.5 - 97.9 ) and 81.9 % ( 95 % CI : 72.0 - 88.5 ) , respectively . At two years , survival was 64.9 % ( 95 % CI : 52.6 - 74.7 ) for transapical patients . CONCLUSIONS This early single-centre experience showed very good safety and performance outcomes in patients treated with the ACURATE prostheses
Specific recommendations for implantation of each prosthesis , taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors , may be needed to reduce the risk of PPI
Aims The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation ( PPI ) after transcatheter aortic valve implantation ( TAVI ) with new-generation prostheses remains debated .
This systematic review analyses the incidence of PPI after TAVI  with new-generation devices and evaluates the electrical , anatomical , and procedural factors associated with PPI .
In addition , the incidence of PPI after  TAVI with early generation prostheses was review ed for comparison .